PD-1 Inhibition Enhances Blinatumomab Response in a UCB/PDX Model of Relapsed Pediatric B-Cell Acute Lymphoblastic Leukemia

Immune therapies such as blinatumomab, CD19-directed bispecific CD3 T-cell Engager (BiTE), have resulted in significant improvements in outcomes for relapsed B-cell acute lymphoblastic leukemia (B-ALL). However, up to half of blinatumomab treated patients do not respond completely or relapse after t...

Descripción completa

Detalles Bibliográficos
Autores principales: Wunderlich, Mark, Manning, Nicole, Sexton, Christina, O’Brien, Eric, Byerly, Luke, Stillwell, Cody, Perentesis, John P., Mulloy, James C., Mizukawa, Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8076590/
https://www.ncbi.nlm.nih.gov/pubmed/33928030
http://dx.doi.org/10.3389/fonc.2021.642466

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8076590/
https://www.ncbi.nlm.nih.gov/pubmed/33928030
http://dx.doi.org/10.3389/fonc.2021.642466

Ejemplares similares